Physician profile
Thomas E Hoffman
NPI 1063435741
$18,475.40
in general payments reported to CMS, 2019-2025
31 companies · $4,198 in 2025
The $4,198 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,197 · 2020: $981 · 2021: $1,437 · 2022: $1,905 · 2023: $4,019 · 2024: $3,739 · 2025: $4,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $1,871 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,068.85 |
| Food and Beverage | $1,871.26 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,623.64 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,090.82 | 2021-2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $890.83 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $758.89 | 2019-2023 | Absorica Ld, Winlevi |
| Allergan, INC. | $626.05 | 2019-2022 | |
| Janssen Biotech, INC. | $603.88 | 2019-2023 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $500.68 | 2019-2025 | Jublia, Siliq, Cabtreo |
| Pfizer INC. | $468.44 | 2019-2025 | |
| Galderma Laboratories, L.P. | $420.53 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $418.10 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $313.10 | 2019-2025 | |
| Lilly USA, LLC | $234.88 | 2019-2025 | Ebglyss |
| Almirall LLC | $223.19 | 2019-2025 | Klisyri |
| Celgene Corporation | $147.77 | 2019 | |
| Amgen INC. | $140.40 | 2020-2025 | Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $139.60 | 2020-2021 | |
| Incyte Corporation | $122.80 | 2021-2025 | Opzelura |
| Ucb, INC. | $87.85 | 2022 | |
| Stemline Therapeutics INC. | $86.05 | 2019 | |
| Epi Health, LLC | $83.16 | 2019-2021 | |
| Dermira, INC. | $80.34 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $74.05 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $69.19 | 2019 | |
| Biofrontera INC. | $67.70 | 2019-2020 | |
| Merz North America, INC. | $64.67 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $38.03 | 2025 | Ycanth |
| Organogenesis INC. | $28.84 | 2024 | |
| Journey Medical Corporation | $21.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.88 | 2019 | |
| Janssen Scientific Affairs, LLC | $17.51 | 2019 | |
| Dermavant Sciences, INC. | $13.23 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.